A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Epoetin beta
Erythropoietin receptor agonist
What it measured
Main measures
Change in Maximum walking distance from baseline to last visit.
Walking and mobility
Who could take part
Progressive MS
Inclusion: Definite MS as determined by the McDonald criteria (Ann Neurol, July 2001)With a primary progressive disease course. Exclusion: Patients who are smokers. Ex-smokers will be required to have stopped smoking for at least 1 month.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the size of the effect, if any, of recombinant human erythropoietin (rhEPO) in improving symptoms of primary progressive multiple sclerosis (PPMS), as measured by Maximum Walking Distance, Multiple Sclerosis Functional Composite (MSFC), Expanded Disability Status Scale (EDSS), Multiple Sclerosis Impact Scale 29 (MSIS), and Neurological Fatigue Index (NFI).
Loading reviews and guidelines…
Related trials
- MS-SMART
Phase 2 · Completed
Missed its main goal
- FLUOX-PMS
Phase 4 · Completed
Result in a paper, not read yet
- EPO-ProgMS
Phase 2 · Status unknown
No result found
- Single Oral Doses Study of Nerispirdine on Visual Functio…
Phase 2 · Completed
No result found
- Amiloride in MS
Phase 4 · Completed
No result found
- Fluoxetine in progressive multiple sclerosis: a placebo-c…
Completed (inferred)
Result in a paper, not read yet
History
Started
Jan 2009
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error